Randomized, Double-Blind, Placebo-Controlled Trial Using Lidocaine Patch 5% in Traumatic Rib Fractures

被引:46
|
作者
Ingalls, Nichole K. [1 ]
Horton, Zachary A. [1 ]
Bettendorf, Matthew [2 ]
Frye, Ira [1 ]
Rodriguez, Carlos [1 ]
机构
[1] Michigan State Univ, Grand Rapids Med Educ & Res Ctr, Grand Rapids, MI 49503 USA
[2] Cent Minnesota Surg, Gen & Bariatr Surg, Sartell, MN USA
关键词
LIDODERM; PAIN;
D O I
10.1016/j.jamcollsurg.2009.10.020
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: The lidocaine patch 5% was developed to treat postherpetic neuralgia. Anecdotal experience at our institution suggests the lidocaine patch 5% decreases narcotic usage in patients with traumatic rib fractures. This trial was developed to define the patch's efficacy. STUDY DESIGN: Patients with rib fractures admitted to the trauma service at our Level I trauma center were enrolled and randomized in a 1 to 1 double-blind manner to receive a lidocaine patch 5% or placebo patch. Fifty-eight patients who met the inclusion criteria were enrolled from January 2007 to August 2008. Demographic and clinical information were recorded. The primary outcomes variable was total narcotic use, analyzed using the 1-tailed Mann-Whitney test. The secondary outcomes variables included non-narcotic pain medication, average pain score, pulmonary complications, and length of stay. Significance was defined based on a 1-sided test for the primary outcome and 2-sided tests for other comparisons, at p < 0.05. RESULTS: Thirty-three patients received the lidocaine patch 5% and 25 received the placebo patch. There were no significant differences in age, number of rib fractures, gender, trauma mechanism, preinjury lung disease, smoking history, percent of current smokers, and need for placement of chest tube between the lidocaine patch 5% and placebo groups. There was no difference between the lidocaine patch 5% and placebo groups, respectively, with regard to total IV narcotic usage: median, 0.23 units versus 0.26 units; total oral narcotics: median, 4 units versus 7 units; pain score: 5.6 +/- 0.4 versus 6.0 +/- 0.3 (mean +/- SEM); length of stay: 7.8 +/- 1.1 versus 6.2 +/- 0.7; or percentage of patients with pulmonary complications: 72.7% versus 72.0%. CONCLUSIONS: The lidocaine patch 5% does not significantly improve pain control in polytrauma patients with traumatic rib fractures. (J Am Coll Surg 2010;210:205-209. (C) 2010 by the American College of Surgeons)
引用
收藏
页码:205 / 209
页数:5
相关论文
共 50 条
  • [41] Estrogen in the prevention of atherosclerosis - A randomized, double-blind, placebo-controlled trial
    Hodis, HN
    Mack, WJ
    Lobo, RA
    Shoupe, D
    Sevanian, A
    Mahrer, PR
    Selzer, RH
    Liu, CR
    Liu, CH
    Azen, SP
    ANNALS OF INTERNAL MEDICINE, 2001, 135 (11) : 939 - 953
  • [42] Budesomide in lymphocytic colitis - A randomized, double-blind, placebo-controlled trial
    Miehlke, Stephan
    Madisch, Ahmed
    Bethke, Birgit
    Wonschik, Susann
    Kuhlisch, Eberhard
    Beckmann, Renate
    Morgner, Andrea
    Mueller, Ralph
    Greinwald, Roland
    Baretton, Gustavo
    Seitz, Gerhard
    Stolte, Manfred
    GASTROENTEROLOGY, 2007, 132 (04) : A131 - A132
  • [43] A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis
    Knobler, RM
    French, LE
    Kim, Y
    Bisaccia, E
    Graninger, W
    Nahavandi, H
    Strobl, FJ
    Keystone, E
    Mehlmauer, M
    Rook, AH
    Braverman, I
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (05) : 793 - 799
  • [44] A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
    Richard, I. H.
    McDermott, M. P.
    Kurlan, R.
    Lyness, J. M.
    Como, P. G.
    Pearson, N.
    Factor, S. A.
    Juncos, J.
    Ramos, C. Serrano
    Brodsky, M.
    Manning, C.
    Marsh, L.
    Shulman, L.
    Fernandez, H. H.
    Black, K. J.
    Panisset, M.
    Christine, C. W.
    Jiang, W.
    Singer, C.
    Horn, S.
    Pfeiffer, R.
    Rottenberg, D.
    Slevin, J.
    Elmer, L.
    Press, D.
    Hyson, H. C.
    McDonald, W.
    NEUROLOGY, 2012, 78 (16) : 1229 - 1236
  • [45] Pterostilbene on Metabolic Parameters: A Randomized, Double-Blind, and Placebo-Controlled Trial
    Riche, Daniel M.
    Riche, Krista D.
    Blackshear, Chad T.
    McEwen, Corey L.
    Sherman, Justin J.
    Wofford, Marion R.
    Griswold, Michael E.
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 2014
  • [46] A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF FISH OIL IN PSORIASIS
    BITTINER, SB
    TUCKER, WFG
    CARTWRIGHT, I
    BLEEHEN, SS
    LANCET, 1988, 1 (8582): : 378 - 380
  • [47] A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression
    E Sherwood Brown
    John Park
    Christine E Marx
    Linda S Hynan
    Claire Gardner
    Domingo Davila
    Alyson Nakamura
    Prabha Sunderajan
    Alexander Lo
    Traci Holmes
    Neuropsychopharmacology, 2014, 39 : 2867 - 2873
  • [48] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NIMODIPINE IN ACUTE STROKE
    MURPHY, JJ
    LANCET, 1990, 336 (8725): : 1205 - 1209
  • [49] FISH OIL IN PSORIASIS - A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL
    BITTINER, SB
    TUCKER, WFG
    BLEEHEN, SS
    BRITISH JOURNAL OF DERMATOLOGY, 1987, 117 : 25 - 26
  • [50] Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism
    Kahaly, George J.
    Riedl, Michaela
    Koenig, Jochem
    Diana, Tanja
    Schomburg, Lutz
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (11): : 4333 - 4341